Biohaven (BHVN) Projected to Post Quarterly Earnings on Thursday

Biohaven (NYSE:BHVN) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($1.56) per share for the quarter.

Biohaven Price Performance

Shares of Biohaven stock opened at $37.24 on Thursday. The business’s 50 day simple moving average is $38.20 and its two-hundred day simple moving average is $42.75. The stock has a market capitalization of $3.77 billion, a P/E ratio of -3.98 and a beta of 1.28. Biohaven has a one year low of $26.80 and a one year high of $62.21.

Insiders Place Their Bets

In related news, Director John W. Childs bought 29,000 shares of the company’s stock in a transaction on Monday, December 30th. The shares were acquired at an average cost of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the acquisition, the director now owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. The trade was a 1.24 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 16.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on BHVN shares. TD Cowen lifted their price target on Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $59.00 price target on shares of Biohaven in a research note on Tuesday, December 17th. Deutsche Bank Aktiengesellschaft assumed coverage on Biohaven in a research note on Tuesday, February 11th. They issued a “buy” rating and a $65.00 price target on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 target price (up from $58.00) on shares of Biohaven in a research note on Wednesday, December 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. Fourteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Biohaven presently has a consensus rating of “Buy” and a consensus price target of $63.15.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.